SEC Form 4 · accession 0001209191-17-037922
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, CFO & COO
Period of report
Jun 1, 2017
Accepted (ET)
Jun 5, 2017 · 6:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2017 | M | 37,383 | $45.11 | A | 163,621 | D | |
| Common Stock | Jun 1, 2017 | M | 18,124 | $48.74 | A | 181,745 | D | |
| Common Stock | Jun 1, 2017 | M | 23,789 | $37.86 | A | 205,534 | D | |
| Common Stock | Jun 1, 2017 | M | 9,062 | $51.75 | A | 214,596 | D | |
| Common Stock | Jun 1, 2017 | M | 10,195 | $38.80 | A | 224,791 | D | |
| Common Stock | Jun 1, 2017 | S | 98,553 | $124.00 | D | 126,238 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $45.11 | Jun 1, 2017 | M | 37,383 | D | — | Feb 4, 2023 | Common Stock | 37,383 | 0 | D |
| Stock Option (Right to Buy)F2 | $48.74 | Jun 1, 2017 | M | 18,124 | D | — | Jul 24, 2022 | Common Stock | 18,124 | 0 | D |
| Stock Option (Right to Buy)F2 | $37.86 | Jun 1, 2017 | M | 23,789 | D | — | Feb 1, 2022 | Common Stock | 23,789 | 0 | D |
| Stock Option (Right to Buy)F2 | $51.75 | Jun 1, 2017 | M | 9,062 | D | — | Jul 12, 2021 | Common Stock | 9,062 | 0 | D |
| Stock Option (Right to Buy)F2 | $38.80 | Jun 1, 2017 | M | 10,195 | D | — | Feb 2, 2021 | Common Stock | 10,195 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1.
- F2Fully vested.